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With the use of cell replacement therapies as a realistic prospect for conditions such as Parkinson’s and
Huntington’s diseases, the logistics of the delivery of cell suspensions to deep brain targets is a topic for consid-
eration. Because of the large cannulae required for such procedures, we need to consider the behavior of cell
suspensions within the cannulae if we are to ensure that the injected cells are distributed as intended within the
target tissue. We have investigated the behavior of primary embryonic cell suspensions of neural tissue, in can-
nulae of different diameters, using a protocol designed to mimic the handling and injection of cells during clini-
cal application. Internal cannula diameter had a large effect on the distribution of cells during their dispensation
from the syringe. In vertical or near vertical cannulae, cells settled toward the tip of the needle, and were dis-
pensed unevenly, with the majority of cells emerging in the first 10–20% of the injectate. In horizontal or near-
horizontal cannulae, we observed the opposite effect, such that few cells were dispensed in the first 80% of the
injectate, and the majority emerged in the final 10–20%. Use of a glass cannula showed that the results obtained
using the horizontal cannula were caused by settling and adherence of the cells on the side of the cannulae, such
that during dispensation, the overlying, cell-free solution was dispensed first, prior to the emergence of the cells.
We show that the behavior of cells in such cannulae is affected by the cannula diameter, and by the material of
the cannula itself. In horizontal cannulae, uneven expulsion of cells from the needle can be ameliorated by regu-
lar rotation of the cannula during the procedure. We discuss the potential impact of these observations on the
translation of cell therapies to the clinic.
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INTRODUCTION
The prospect of replacement cell therapies for diseases
of the central nervous system (CNS) is both real and
exciting. Neurodegenerative diseases, such as Parkinson’s
disease (PD), Huntington’s disease (HD), multisystem
atrophy, amyotrophic lateral sclerosis, multiple sclerosis,
or retinal degeneration, and brain injuries, such as ische-
mia or traumatic brain injury, might soon be treated by
the implantation of cells into affected brain areas. The
aim of these therapies is to replace lost cells (whether
neurons or glia) or to use cells as neurochemical or tro-
phic delivery systems in the depths of the brain, and
thereby alleviate the clinical symptoms of the condi-
tions concerned.
Currently, such therapies are mainly experimental, not
in widespread use, and depend on primary sources of
cells such as human embryos. However, the development
of safe, reproducible stem cells capable of providing a
steady source of implantable cells is becoming a reality
and, with it, the prospect of moving CNS cell therapies
into the mainstream (2,4,6,12,23,36,40,41).
In animal models, behavioral deficits associated with
parkinsonian or striatal lesions have been shown to be
ameliorated by grafting with embryonic ventral mesen-
cephalon or ganglionic eminence, respectively, at the
appropriate early developmental stages (10,13,38). In rats
and mice, this involves the injection of a few microliters
of a cell suspension containing several hundreds of
thousands of cells, into brain areas up to 5–6 mm from
the brain surface. The cannulae used are small, typically
0.15–0.25 mm internal diameter (ID), and the loading and
positioning of the cannula and subsequent injection of the
cells into the brain is relatively quick, such that the entire
procedure may be completed in 5–10 min.
Translation of such cell therapies from animal models
to the clinic poses a number of challenges (34), not least
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the scaling of cell injection protocols for use in the
human brain. As in animal models, injection of cells and
substances into the brain in the clinic is performed using
stereotaxic surgery. Cells are preloaded into a syringe,
which is then attached to a stereotaxic frame mounted on
the patient’s head. Subcortical, target structures such as
the caudate nucleus or corpus striatum are deep in the
brain and require a long, thin cannula of sufficient rigidity
to penetrate accurately to the target site without injury to
the overlying structure. In addition, the number of cells to
be injected will be in the millions or tens of millions, and
a cannula or syringe of considerable volume is required
(25). The behavior of cells in suspension within such
large-volume cannulae is the subject of the present work.
We have investigated the behavior of cell suspensions
prepared from embryonic rat CNS using metal and glass
cannulae of different IDs. Cannulae were loaded with cell
suspension before being attached to a cannula holder and
positioned either vertically (±30°) or horizontally (±30°)
and then allowed to sit for up to 20 min. This protocol was
intended to mimic the positioning and handling of cannulae
during stereotaxic surgery for patients being treated either
sitting upright or prone (which can vary in different deep
brain stimulation and implantation surgeries, both under
general and local anesthesia). Following the settling period,
cells were dispensed from the cannula in 8 × 2.5-µl aliquots
over a period of 2 min in order to determine their distribu-
tion within the cannula after settling and how this might
affect the distribution of cells along the injection track. The
use of glass cannulae allowed direct visualizationof cell set-
tling and for photographs to be taken prior to analysis of cell
distributionwithin the cannulae at different time points dur-
ing both settling and collection.
MATERIALS AND METHODS
Cell Suspensions
Whole embryonic rat brains of either 12 days (E12) or
14 days (E14) gestation were collected from time-mated
dams (adult rats supplied by Charles River, Margate,
UK), dissected in Hank’s balanced salt solution (Life
Technologies, Paisley, UK). The brains were then cut into
smaller pieces and transferred to a 1.5-ml centrifuge tube
containing 1 ml of Dulbecco’s minimum Eagle’s medium
(DMEM; Life Technologies). After a further two washes
in DMEM, tissue was incubated for 20 min in 1 ml of
prewarmed TrypLE Select enzyme (Life Technologies)
containing 20 U/ml of the endonuclease dornase alfa
(DA; Roche, Welwyn Garden City, UK).
Tissue digestion was stopped by washing 2 × 1 min in
prewarmed dissociationmedium (DMEM containing 20 U/
ml DA). Following the final wash, tissue was placed in
200 µl of dissociation medium and dissociated by repeated
trituration of 150 µl of the suspension each time using stan-
dard, plastic pipette tips (first P1000 then P200) to a “near
single” cell suspension. Cell numbers and viability were
determined using 2 × 2-µl samples in trypan blue (Life
Technologies) exclusion assays. Finally, cells were gently
spun down using centrifugationand resuspended in dissoci-
ation medium to a final cell concentration of 100,000 cells/
µl. In order to assess the suitability of rat embryonic
suspensions for this work in a pilot stage, cell suspensions
were also prepared from human embryonic brain tissue
using the same protocol, and the cell diameters from human
and rat preparationswere compared.Human fetal tissuewas
collected with local research ethics committee approval
(Bro Taf, Pontyclun, Mid Glamorgan, UK), with full con-
sent of the maternal donor, as part of the MRC-sponsored,
South Wales initiative for transplantation (SWIFT) pro-
gram, operating under license from the UK Human Tissue
Authority. All animal experiments were conducted in
accordance with local ethical review and Home Office
licenses according to the UKAnimals ScientificProcedures
Act 1986.
Latex Beads
Previous work used microfluidic techniques to measure
the density of single cells and employed polystyrene beads
with an equivalent density showing that they performed like
live cells (erythrocytes) (16). As human erythrocytes are
similar in size to the cells used here (6–8 mm), the same
nonionic, polystyrene (white) beads (Life Technologies)
were used to better visualize settlingusing the current proto-
col, although cell adhesion propertiesmay differ.
Cannulae
Metal cannulae were prepared from stainless steel tub-
ing (Cooper’s Needle Works, Birmingham, UK) cut to
length and filed to a smooth, beveled end. The gauges
used were 18 (ID 0.83 mm), 21 (ID 0.51 mm), and 25
(ID 0.26 mm), which for convenience are denoted as 0.8-,
0.5-, and 0.25-mm cannulae. For a given volume of cell
suspension, as the ID of the cannula decreases, there is a
dramatic increase in the length of cannula required. In the
present experiment, the approximate volume per unit
length for each cannula was as follows: 0.8-mm ID: 5 ml/
cm, 0.5-mm ID: 2 ml/cm, and 0.25-mm ID: 0.5 ml/cm.
Glass cannulae consisted of capillary electrode tubes
with a nominal ID of 0.8 mm (Clark Electromedical Instru-
ments, Edenbridge, Kent, UK). Between experiments, can-
nulae were cleaned by flushing with sterile saline solution
followedby 70% ethanol, before air drying.
Loading and Dispensing
Cannulae were attached via a short length of silicone
tubing to a 100-µl Hamilton syringe mounted on an elec-
tronic syringe driver (model 22; Harvard Apparatus,
Holliston, MA, USA). To avoid capillary and mixing
effects, the syringe, tubing, and cannula were not filledwith
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priming fluid. To avoid the effects of temperature changes
during the experiment, all equipment, media, and cell
suspensions were allowed to equilibrate to room tempera-
ture before use. For loading of cells, the cannula was
clamped in a vertical position and, following gentle mixing
of the cell suspension, loaded with 20 µl (0.8- and 0.5-mm
ID cannulae) or 5 µl (0.25-mm ID) of cell suspension. The
cannula was then immediately reoriented to one of five
angles designed to mimic the range of orientations encoun-
tered during intracranial surgery. The orientations used
were vertical; 30° from vertical; horizontal; 30° from hori-
zontal, tip up; and 30° fromhorizontal, tip down. Cellswere
then allowed to settle for 20 min, the period of time esti-
mated for the transfer and attachment of the syringe to the
stereotaxic frame and the lowering of the needle into the
brain prior to injection. After the settling period, cells were
extruded from the cannula in order to determine their distri-
bution within the cannula and how this might affect their
distribution following injection. The syringe driver was set
to dispense at 10 ml/min, and 8 × 2.5-ml aliquots were col-
lected into eight sequentially numbered PCR tubes. The
number of cells collected in each aliquot was determinedby
counting on a hemocytometer. Each 2.5-µl aliquot was
diluted using physiological phosphate-buffered saline to a
final volume of 20 µl, and 10-µl samples were then loaded
on opposite sides of a hemocytometer, and the numbers of
cells counted using 10× objective on an inverted micro-
scope (OlympusCK40). Themean cell count was then used
to estimate the total number of cells collected in each ali-
quot. The collected data are presented as the proportion of
cells collected in each aliquot expressed as a percentage of
the total collected.
Rotation
In order to ameliorate settling in horizontal orientations,
0.8-mm metal or glass cannulae were loaded with cell sus-
pension as previously described, then rotated through 180°
along their long axes once every minute during the 20-min
settling period. After 20 min, cells were collected in eight
aliquots and counted as previously.
Photography
Photographs of glass cannulaewere taken during settling
and extrusion of the cell suspension in both vertical and hor-
izontal orientations, using a Canon 95 IS compact camera.
Statistical Analysis
To determine the effects of orientation and cannula
size on the distribution of cells in the collected aliquots,
data were analyzed by multifactorial analysis of variance
(GenStat 16th edition; VSN International, Oxford, UK)
with separate analyses undertaken for each experiment
with cell source, cannula orientation, and internal diame-
ter as between-sample factors and aliquot as the within-
sample factor. Post hoc comparisons were undertaken
using Newman–Keuls and Sidak’s tests as appropriate.
RESULTS
Cell Diameters
To determine whether or not rat embryonic cells were a
suitable proxy for human cells, a comparison was made of
cell diameters in cell suspensions prepared from either rat or
human embryonic neural tissues. Rat embryos were aged
E12–14, and human embryos were of an equivalent devel-
opmental age ranging from7 to 9 weeks postconception.
As shown inTable1, rat cellswereon average12%larger
than human cells in suspension [t(1121) = 6.210, p < 0.001],
and rat cell suspensionsdisplayedawider rangeof cells sizes
[F(752, 371) = 1.418, p < 0.001].Although significant,not
least due to the large sample sizes, the differencesbetween
human and rat cell diameters were small, and the range of
human cell diameters was encompassed by that of the rat.
Rat cells were considered to be a suitable surrogate for the
currentwork.
Cannula Experiments
Settling experiments were all conducted using a cell
suspension containing 100,000 cells/ml and using a 20-min
wait period between cannula filling and collection of the
cells in eight aliquots. The following data report the propor-
tion of cells collected in each aliquot in each experiment.
The data from each experiment consist of a minimum of
three replicates, and error bars represent the standard errors
of themeans.
The 0.8-mm Metal Cannula
The distribution of cells collected from each aliquot
dispensed from 0.8-mm cannulae at each orientation are
shown in Figure 1. There was a marked difference
between the proportions of each suspension extruded in
Table 1. Comparison of Rat and Human Cells in Suspension
Embryo
Cell
Suspensions
Cells
Measured (n)
Min.
(mm)
Max.
(mm)
Mean*
(mm) SD†
Rat 11 752 3.19 11.19 5.96 1.31
Human 7 371 3.51 9.33 5.31‡ 1.10‡
‡Significant differences by *Student’s t-test and †F ratio test, respectively, both p < 0.001.
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each aliquot depending upon the cannula angle [Angle ×
Aliquot, F(28, 91) = 147.33, p < 0.001].
Vertical Orientations
Inspection of Figure 1A indicates that cells dispensed
from the cannulae oriented either vertically or at 30° from
vertical exhibited a marked skew in the numbers of cells
toward the first two collected aliquots. On average 65–75%
of cells were counted in the first extruded aliquot, with
fewer than 5% counted in the final three aliquots combined.
Horizontal Orientations
Conversely, the distributions of cells extruded from can-
nulae oriented either horizontally or 30° above or below the
horizontal were also greatly skewed, but in the opposite
direction toward the later aliquots. On average <1% of cells
were collected in each the first six aliquots, <10% in the
seventh aliquot, and around 90% in the final aliquot.
The 0.8-mm Glass Cannula
In order to visualize and illustrate the behavior of cell
suspensions in the 0.8-mm cannula, the initial experiment
was repeated using a 0.8-mm glass cannula. Photographs
were taken during the 20-min settling period and after
each aliquot was dispensed during the expulsion phase.
Vertical Cannula
Figure 2 shows the 0.8-mm glass cannula in a vertical
orientation, photographed at 2-min intervals during set-
tling. Cells were initially well mixed (T0). Settling of
cells in the cannula was evident after 4 min and was pro-
nounced 6 min after loading. After 20 min, the majority
of cells were located near the end of the cannula, in the
bottom 3–4 mm (of the total 40 mm) of the height of the
liquid in the cannula. As a result, most cells were
extruded within the first (2.5 ml) aliquot.
Horizontal Cannula (Settling)
Figure 3 shows settling of the cell suspension in a hori-
zontally oriented glass cannula during the 20-min settling
period. Cells were initially well mixed, but settled quickly
so that after 20 min there was a dense layer of cells at the
bottom of the cannula, above which was clear, mainly cell-
free solution. The use of white-colored latex beads of simi-
lar size and density to the cells (16) allowed higher power
images of the settling process to be obtained. A clear layer
of fluid was visible at the top of the cannula after just 2 min,
and by 6 min, beads were only visible in the bottom half of
the cannula. The settled layer at the bottom of the cannula
was clearly visible after just 4 min, suggesting that even
after a short period of settling, some cells might be adherent
to the cannulawall.
Vertical Cannulae (Expulsion)
Figure 4 shows the behavior of the settled cell suspen-
sion during extrusion of the cells after 20 min of settling.
The layer of settled cells appears to be adherent to the
lower surface of the cannula. As the needle is evacuated,
the overlying, largely cell-free medium is expelled first,
and the layer of settled cells accumulates in front of the
advancing plunger, only emerging once all of the overly-
ing fluid has been dispensed.
Quantitation
Results were similar to those seen with the metal can-
nula. In the glass cannula, oriented either vertically or at
30° from vertical, on average, 50–75% of cells were col-
lected in the first two extruded aliquots, with most of the
remaining cells emerging in aliquots 2–7, and less than
5% of cells collected in the final aliquot (Fig. 5A). In
0.8-mm glass cannulae oriented either horizontally, at 30°
from horizontal with the needle tip pointing up, or at 30°
from horizontal with the needle tip pointing down, on
average, <1% of cells were collected in the first six
aliquots, <10% in the seventh aliquot, and >80% of cells
emerging in the final aliquot (Fig. 5B). The effect of
Figure 1. The 0.8-mm cannula quantitation. Proportions of
total cells (%) collected in each aliquot, following a 20-min
settling period in vertical (A) and horizontal (B) orientations
of the cannulae. Vertical bars are SEMs.
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cannula angle on the proportions of cells extruded in each
aliquot was again very highly significant [Angle ×Aliquot,
F(28, 119) = 35.98, p < 0.001].
In summary, settling of cells in 0.8-mm cannulae,
whether made of metal or glass, resulted in a skewed dis-
tribution of the extruded cells in all cannula orientations.
In vertical orientations, settling of the cells toward the
cannula tip resulted in extrusion of most of the cells in
the first one to two aliquots. In horizontally oriented
aliquots, the settled cells were adherent to the lower wall
of the cannula, remaining stuck to the wall until physi-
cally dislodged by the advancing plunger, and resulting in
a collection of the cells in the final one to two aliquots. In
a surgical situation, such behavior of cells within the can-
nula would be likely to lead to uneven distribution of
cells in the host brain during implantation.
The 0.5-mm Metal Cannula
Using the 0.5-mm cannulae oriented either vertically
or at 30° from vertical, there was again a marked settling
of the cells in the cannula, resulting in a skewed distribu-
tion of cell numbers in the collected aliquots (Fig. 6A).
On average, 30–45% of cells were collected in the first
extruded aliquot. Most of the remaining cells emerged in
aliquots 2–7, with less than 5% of cells being collected in
the final aliquot. Conversely, when the cannulae were ori-
ented either horizontally or 30° above or below the hori-
zontal, there was again a skewed distribution of cell
numbers in the collected aliquots opposite to that seen in
the vertical orientations (Fig. 6B). On average <1% of
cells were collected in the first six aliquots, <20% in the
seventh aliquot, and >70% of cells emerging in the final
aliquot. The differences between the distributions of cell
extrusions at different cannula orientations was again
highly significant [F(28, 91) = 53.91, p < 0.001] and was
similar in pattern to that seen using the 0.8-mm metal
cannula, though not quite as marked (compare Fig. 1 vs.
Fig. 6).
The 0.25-mm Metal Cannula
Using the thinnest metal cannulae of 0.25 mm ID, of the
same order of magnitude as those used in rodent studies,
when oriented either vertically or at 30° from vertical there
was still an observable settling of the cells in the cannula
resulting in a skewed distribution of cell numbers in the col-
lected aliquots (Fig. 7A). Conversely, when the 0.25-mm
metal cannulae were oriented either horizontally or ±30°
from horizontal, there was again a skewed distribution of
cell numbers, but in the opposite direction toward the later
collected aliquots (Fig. 7B). Although the effect of angle on
the profiles of cell extrusion was again highly significant
[Angle×Aliquots,F(28, 133) = 8.20, p < 0.001], the skews
in either direction were not nearly as pronounced as that
seenwith larger cannulae (compareFig. 7 vs. Figs. 1 and 6).
In summary, a reduction of internal cannula diameter
from 0.8 to 0.5 mm had little effect in horizontally oriented
cannulae, but in vertically oriented cannulae, more cells
were collected in earlier aliquots. In cannulae of 0.25 mm
ID, the effect was more dramatic, and the skewed distribu-
tion of collected cells was largely alleviated [Diameter×
Angle ×Aliquot, F(84, 434) = 15.43, p < 0.001]. Thus, in
vertically oriented cannulae, cells were widely distributed
across the first six aliquots, while in horizontally oriented
cannulae, cells were widely distributed across aliquots
Figure 2. Photographs of the settling of cell suspensions in the 0.8-mm vertical glass cannula. The settling of cell suspensions in
the 0.8-mm vertical glass cannula is shown, starting immediately after the filling of the cannula with cell suspension (T0) then at
2-min intervals over the 20-min settling period. Settling was evident after 4 min and prominent after 8 min. Cell clumping was also
evident after 8 min followed by continued settling toward the cannula tip.
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Figure 3. Photographs of settling in the 0.8-mm horizontal glass cannula. The settling of cell suspensions in the 0.8-mm horizontal
glass cannula is shown, starting immediately after the filling of the cannula with cell suspension (T0) then at 2-min intervals over
the 20-min settling period. Top: A layer of clear fluid at the top edge of the cannula was apparent after 4 min, which became pro-
gressively larger as the cells settled in to a compact layer on the bottom surface. Bottom: Settling at high magnification visualized
using white latex beads of similar size and density to embryonic neural cells. Settling is apparent after 2 min. At 4 min, a layer of
settled cells is visible. At 8 min, the top half of the cannula is clear of cells.
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2–8. Note that in standard rat stereotaxic surgery, the pre-
dominant orientation is vertical, although there have been
specific surgical targets where a relatively oblique orien-
tation has been used (11).
Cannula Rotation
It was hypothesized that, in order to limit the effects
of settling in the horizontally oriented cannula, periodic
rotation of the cannula along its axis might serve to main-
tain cells in suspension and to prevent the adherence of
settled cells to the wall of the cannula. Using the 0.8-mm
glass or 0.8-mm metal cannulae loaded with cell suspen-
sion as previously, the horizontally oriented cannula was
rotated through 180° at 1-min intervals throughout the
20-min waiting period and the contents collected in eight
aliquots as previously described. Figure 8 shows the
results of rotations from both types of cannula (A and B,
respectively). In the metal cannula, rotation appeared to
ameliorate cell settling. Unlike from the nonrotated can-
nula, cells were collected in all aliquots, with a small
peak in aliquot 1. It fell to a minimum in aliquots 6 and
7, and a large peak as previously in aliquot 8 [Rotation×
Aliquots, F(7, 84) = 9.87, p < 0.001]. This is consistent
with some settling as previously observed, but with a
proportion of cells remaining suspended in solution and
emerging early in the injection with the overlying fluid.
Figure 4. Photographs of the expulsion of the settled cell suspension from a 0.8-mm horizontal glass cannula. The expulsion of the
settled cell suspension from a 0.8-mm horizontal glass cannula is shown, starting immediately after the 20-min settling period (T0),
then at 15-s intervals during the collection of each of the eight 2.5-µl aliquots. The settled cells collect together as the plunger
advances to emerge only after all of the overlying fluid has been expelled.
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In the glass cannula, cell distribution was even more
evenly distributed across the eight aliquots in the rotating
than the stationarycannulae [Rotation×Aliquots,F(7, 63) =
130.45, p < 0.001] such that settling was almost com-
pletely eliminated. This suggests that the adhesion (and/or
cohesion) of the settled cell layer is less in the glass than
in the metal cannula [Cannulae × Rotation × Aliquots,
F(7, 147) = 130.45, p < 0.001].
DISCUSSION
Cell therapies targeting deep anatomical structures such
as subcortical nuclei in the brain will require the use of long
cannulae that have either large IDs or are attached to large-
diameter syringes at their distal ends. When such cannulae
are loaded with cell suspensions, the possibility of cell sedi-
mentation during the course of the surgical procedure, and
the potential for uneven deposition of cells along the injec-
tion tract during implantation needs to be considered.
Unequal deposition of cells may result in poorer survival or
poorer integration of cells in the host brain or in a failure to
properly access the target region for which the therapy is
intended. In recent cell therapy trials for PD, posttherapy
side effects in the form of graft-induced dyskinesias have
been observed,whichmay, in part, have been due to the for-
mation of dopamine “hot spots” in the host brain resulting
in abnormal activation of the neural circuits involved (26).
Additionally, when targeting deep structures, it is desirable
to avoid repeated penetrationswith the injection cannula. In
order to minimizedamage to both the target tissue and over-
lying structures and in order to achievewidespread distribu-
tion of cells in the target tissue, injection protocols usually
involve injection of cells at several different depths along
the same needle track. As a result, both the volume of cells
loaded into the syringe and the size of cannula requiredwill
be large, and the time between initial loading of the cannula
and expulsion of the last cell depositmay be lengthy.
Note that the potential for tissue trauma when injecting
with large needles must be considered. In animal models,
fine glass cannulae (<100 mm) have been shown to cause
less damage than larger metal cannulae to the host brain
(30,31). However, glass cannot be used in the clinic
because of lack of rigidity and the possibility of fragmenta-
tion within the host. Additionally, the use of a very fine
Figure 5. The 0.8-mm glass cannula quantitation. Proportions
(%) of total cells collected in each aliquot, following a 20-min
settling period in vertical (A) and horizontal (B) orientations
of the cannulae. Vertical bars are SEMs.
Figure 6. The 0.5-mm metal cannula quantitation. Propor-
tions of total cells (%) collected in each aliquot, following a
20-min settling period in (near) vertical (A) and horizontal
(B) orientations of the cannulae. Vertical bars are SEMs.
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cannula would require more extensive dissociation of the
donor tissue with the potential for trauma to the donor cells
and a potential decrease of both viability and survival.
Experiments in rats using different diametermetal cannulae
showed a detrimental effect on graft survival using a
2.5-mm cannula (7) as a result of which subsequent clinical
trials adopted a 1.0-mmdiameter cannula.
Thus, metal cannulaewith IDs in the 0.25–1.0-mm range
provide a balance between tissue trauma and optimal cell
delivery, and there have been a number of clinical trials for
the treatment of PD, ALS, and HD, which illustrate this
point. Trials using nondissociated cells have used relatively
large injection cannulae with IDs of 0.33 mm (5,14),
0.4 mm (36), 0.5 mm (9,28), 0.6 mm (15,32), 0.69 mm
(34), 0.8 mm (27), and 1.0 mm (19). However, for reasons
detailed previously, trials using dissociated cell suspensions
have also employed large cannulae in the range 0.5 mm to
0.8 mm ID (8,24,28,33,35,37).
The behavior of cell suspensions within such cannulae
will be influencedby a number of factors. In the current arti-
cle, we have considered the material of the cannula itself,
cannula diameter, cannula angle during surgery, and
cannula rotation. The amount of time between filling of the
cannula and injection of the cells into the target area will
also be important, though this is not reported in the litera-
ture. The protocol used in the present work was designed,
following discussions with neurosurgeons, to represent a
maximal interval between filling of the cannula and cell
injection, allowing time for the syringe to be transported to
the patient, affixed to the stereotaxic frame, and lowered
into the target structure. In practice, the surgical apparatus
and protocols used by others may be longer or shorter than
those used here. Although the specific combinations of cell
preparation, density, timing, instruments, and angles of
delivery will not match exactly those used in any particular
clinical trial, the large and consistent results observed indi-
cate that these factors must be considered and empirically
validated for each variant prior to use in surgical practice.
The present results show clearly that there may be con-
siderable settling of embryonic neural cell suspensions in
large-diameter cannulae (0.8 and 0.5 mm ID), regardless of
the angle of orientation, but that settling had opposing
Figure 7. The 0.25-mm metal cannula quantitation. Propor-
tions of total cells (%) collected in each aliquot, following a 20-
min settling period in vertical (A) and horizontal (B) orientations
of the cannulae. Vertical bars are SEMs.
Figure 8. The effect of rotation in the 0.8-mm horizontal can-
nula. Proportions of total cells (%) collected in each aliquot,
following a 20-min waiting period during which time the can-
nula was rotated around its long axis at intervals of 1 min.
(A) Metal cannula. (B) Glass cannula. Data are plotted against
nonrotated data, collected previously, for comparison. Error
bars are SEMs.
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effects, depending on the gross orientation of the cannula.
In a vertical cannula, settling caused an accumulation of
cells near the tip of the needle, and during ejection of the
cells from the cannula, the majority of cells emerged in the
first part of the injection. In a surgical setting, where cells
are intended to be injected as multiple deposits, from
deepest to shallowest, along the same injection track, this
would result in a bolus of cells dispensed at the bottom of
the needle track and few cells implanted in the overlying tis-
sue (Fig. 9A). By contrast, in a horizontal cannula, the
reverse situation was observed, with few cells emerging in
the early part of the injection and the great majority of cells
emerging in the last one to two aliquots of the injection. In a
prone patient, this would result in few or no cells dispensed
in the deepest parts of the target tissue and the majority of
the transplanted cells deposited at the top of the needle track
(Fig. 9B). Deviation of the cannula by ±30° from either the
vertical or horizontal did not significantly alter the observed
skewed distributionof the collected cells.
Observationof settling and expulsion of cell suspensions
in a 0.8-mm ID glass cannula provided an explanation for
the skewed distribution of collected cells when using the
Figure 9. The effects of settling on tissue distribution in the target tissue. Where the desired placement is to distribute cells in mul-
tiple deposits throughout the target structure (gray shaded area in diagram), settling may disrupt the even distribution of cells.
(A) In a vertical orientation, settling will cause the majority of cells to be deposited at the bottom of the injection tract (dashed
line). (B) In a horizontal orientation, settling will cause the majority of cells to be deposited at the top of the injection tract.
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0.8-mm ID metal cannula. In the vertical glass cannula,
cells could clearly be seen collecting near the tip of the nee-
dle, which then quickly emerged within the first few
microliters on expulsion. In the horizontal orientation, the
skewed distribution of collected cells was seen to be caused
by adherence of the settled cells in a layer on the wall of the
cannula, where they remained until they were forced to
detach by the advancing plunger. As a result, during expul-
sion, the overlying, cell-poor fluid was dispensed first,
while the settled cells collected in front of the moving
plunger, emerging enmasse, in the last one or two aliquots.
Use of a 0.5-mm ID cannula partially alleviated settling
effects in the vertical, but not horizontal orientations,
whereas use of a smaller cannula of 0.25 mm ID signifi-
cantly alleviated settling effects in all orientations. This
resulted in a muchmore even distribution of cells in the col-
lected aliquots. Based on what was observed previously in
the glass cannula, this was likely due to the final packed
volume of the settled cells, which was large relative to the
internal volume of the cannula, leading to a correspond-
ingly small volume of cell-freefluidwithin the needle.
Routine use of small-diameter cannulae would seem
an obvious solution to the cell-settling phenomenon
described here. Provided that the settled volume of cells
is close to the internal volume of the cannula, and there
are no significant areas of cell-free medium within the
syringe, the skewed distribution of ejected cells could be
largely avoided. However, it should be noted that,
although this small size is similar or larger than the can-
nulae used in most rodent experiments on which clinical
trials are initially developed (including preclinical valida-
tion of human cells following rodent xenotransplantation),
0.25 mm ID is significantly smaller than any clinical
instrument in current use. A cannula of small ID becomes
impractical for injections larger than a few tens of
microliters in volume because as the ID of the cannula
decreases, the length of cannula required increases as the
square of the cannula’s radius. Thus, for a modest injec-
tion volume of 20 ml, a cannula of 0.25 mm ID needs to
be more than 41 cm long. A cannula with an ID of
0.1 mm would require a cannula 200 cm long. While it is
possible to use a small-diameter cannula connected to a
syringe, this merely has the effect of transferring the bulk
of the cell suspension from the cannula to the syringe
itself and the potential for the settling effects within the
syringe still remains. A similar effect might be achieved
by increasing the cell concentration used, likewise to
increase the settled cell volume within the needle. There
are limitations to this approach also, as there will be
physical limits to the concentration of cells that can be
loaded and ejected from the cannula without blocking.
The much reduced buffering and nutrient capacity of
smaller volumes of the injection medium may also be
detrimental to the health and survival of the cells.
We have shown here that the skewed distributionof cells
in horizontally oriented cannulae can be ameliorated by
rotation of the cannula at regular intervals during the proce-
dure. This effect was more pronounced in glass cannulae
than in metal, suggesting that the interaction between the
cells and the cannula material is a factor worthy of further
investigation.Whether the adherence of the cell layer to the
wall of the cannula (and/or the adherence of cells to each
other) is due to chemical, physical, or charge effects has not
been studied here, but all of these might conceivably be
manipulated to decrease adhesion even if settling effects in
solution cannot be avoided. The present data suggest that, in
prone patients, the use of cannula rotation during the injec-
tion is a viable strategy. Indeed, there are examples of the
use of this strategy in the literature. In trials carried out in
Sweden using the 0.8-mm ID Rehncrona injection device
(8,39), the needle was rotated at regular intervals during the
procedure (personal communicationwith Dr. S. Rehncrona).
Similarly, in a clinical trial for PD carried out by Mendez et
al., the injection protocol incorporates rotations of the can-
nula between deposits (29). Postmortem examination of the
brains of patients from both of these studies were able to
show surviving grafts well distributed within the target tis-
sue (3,20). Similarly, in a clinical trial for stroke using a
cannula with an ID of only 0.25 mm, attached to either a
250-ml or 100-ml syringe, the syringe and cannula were
rotated during the procedure in order to “maintain a mixture
of cells within the solute” (18). In order to counter settling,
it is clearly important to keep the main volume of cell sus-
pension agitated in some way. For a syringe with a fixed
needle, rotation of the syringe at regular intervals during the
procedure is likely to be sufficient. As an alternative,where
a large volume syringe is connected via fine caliber tubing
to a cannula, rocking or rotation of the syringe at intervals
might also be possible.
The present study is essentially empirical, and a
detailed consideration of the physics of cell sedimentation
is beyond the scope of the current work. However, we
can infer how changes in cell size or medium viscosity
might affect the rate of settling within the cannula from
Stokes’ law on the settling speed of small spheres in a
fluid medium. According to this, the settling velocity (V)
of a cell is given by the formula
V ¼ g D2  ðrc−rÞ=18m
where g is gravitational acceleration, D is the cell diam-
eter, rc is cell density, r is fluid density, and m is fluid
viscosity (21). Based on this relationship, for a given
cell density, settling velocity increases with the square
of the cell diameter, and larger cells settle more quickly
than small ones. Similarly, we would expect the settling
velocity of clumps of cells to be high relative to single
cells of the same type. This is an important consider-
ation. In the clinical setting, cell suspensions might well
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be only partially dissociated in order to minimize cell
trauma and may contain clumps of cells likely to settle
more quickly than the relatively well dissociated cell
suspensions studied here.
In contrast, the viscosity of the medium has an inverse,
linear effect on settling such that a doubling of medium vis-
cosity will effectivelyhalve the settling velocity of the cells.
Therefore, slowing down the sedimentation rate of cells
within the cannula by increasing the viscosity of the
medium is another strategy worth consideration. Alginates
(naturally occurring complex sugars extracted from brown
seaweeds) can be used to increase the viscosity of physio-
logical solutions, without toxicity to the cells concerned.
These have been used in a variety of in vitro applications
(e.g., microfluidics) and for the injection of cells into the
vascular system in animal models (22) or as hydrogels to
construct tissue scaffolds (1,17).
There are a number of other factors, not investigated in
the present work, which might have an effect on cell behav-
ior in large cannulae. In the translation of the current
protocols to the clinic, different factors might further ame-
liorate or exacerbate cell settling. The time between filling
of the cannula and injection is clearly critical and, based on
the current data, should be kept as short as possible. Higher
cell concentrations will result in larger packing volumes of
the settled cells and, by default, better distribution of the
cells from the needle. However, if these are too high, then
cell health and even flow of the cell suspension within the
needle may be compromised. The effects of temperature
may also need to be considered. All of the experiments
reported here were carried out at room temperature, but in a
clinical setting, cell suspensions may be kept chilled or on
ice before loading into the injection cannula (at room tem-
perature) and then be lowered into the tissue to be injected,
which is at body temperature. The increase in temperature
may cause expansion of the cell preparation, and convec-
tion currents may be set up within the cannula, and the
effects of this on the settling process is unclear. Cannulae
made from different materials might also have an effect. In
the current work, the ameliorating effect of rotation was
greater in glass cannulae than in metal. Whether this was
due to the surface properties of the material itself or the
effects of other factors such as electrical charge or tempera-
ture stability is not known. In a horizontal cannula, adhe-
sion of the cell layer to the cannula wall prevented the
movement of cells with the overlying fluid during injection,
so that low friction coatings of the internal wall of the can-
nula, such as silicone or Teflon®, might be considered to
overcome this.
The present results do not preclude the use of large can-
nulae for cell therapies in the clinic; indeed, such cannulae
have already been used in a number of trialswith successful
outcomes. Rather, the data point to the limitations of large
cannulae, particularly for large volumes of single cell
suspensions and where lengthy, multideposit procedures
are proposed. When using such cannulae, procedures
should be validated using the actual instruments and deliv-
ery protocols proposed, so that potential problems of
uneven cell deliverymay be identified and addressed before
commencementof the clinical trial.
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